Anish Bhatnagar

CEO Anish Bhatnagar sells 699,095 shares for $47,271,960.09 across 12 transactions on 2025-03-27, reducing holdings by 54.8%

Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics, executed a substantial liquidation of 699,095 shares (699.1K shares) across 12 separate transactions on 2025-03-27, generating $47,271,960.09 at a blended average price of $67.62, and reducing his post-transaction holdings to 577,076 shares (577.1K shares)—a 54.8% reduction of his pre-transaction stake. The sale occurred near the stock's 52-week high of $71.99 (current price $71.45 is -0.8% from peak), with the stock up 46.4% over 30 days and 59.0% over 90 days, indicating a period of significant appreciation preceding the sale. The CEO's prior trades at SLNO show 2 of 2 measurable sales were well-timed at the 90-day mark (both posted negative 90-day returns of -8.2% and -9.8%), suggesting a pattern of selling ahead of declines at this ticker. The company remains unprofitable (net income $-76,616,000.00 for the latest full fiscal year) despite strong revenue growth of 138.8%, creating a fundamental tension between near-term momentum and long-term cash burn.

Soleno CEO Anish Bhatnagar sells 21.1K shares (21,091) for $965,515.52 across 3 transactions at blended avg $45.78.

Anish Bhatnagar, the company's Chief Executive Officer, executed 3 separate sales totaling 21,091 shares for $965,515.52 on 2025-01-02 and 2025-01-03, reducing his holdings by 2.9% to 698,462 shares. The sales occurred at prices ($45.37, $45.92, $46.18) that are currently above the current market price of $45.90, though the stock is down 6.6% over 30 days and down 11.7% over 90 days from the transaction date. His prior trades at Soleno show mixed timing: of 5 prior sells at this ticker, only 2 were well-timed (negative 90-day returns), indicating roughly 40% accuracy at this specific company, which differs materially from his cross-ticker track record of 20.00% well-timed rate across 20 prior sells. The company remains unprofitable (net income $-76,616,000.00 for the latest full year) despite strong revenue growth of 138.8%, which contextualizes the transaction against underlying operational losses.

CEO Anish Bhatnagar sells 21,633 shares at blended avg $49.43 for $1.1M at unprofitable biotech with 138.8% revenue growth

Anish Bhatnagar, CEO of SOLENO THERAPEUTICS INC (SLNO), executed 2 separate sales totaling 21,633 shares for $1,069,306.23 on 2024-10-01, reducing his holdings by 2.9%. The company is unprofitable with a net income of $-21,854,000.00 over its most recent full fiscal year, though it reported annual revenue growth of 138.8%. His prior trades at SLNO (5 sales since 2024-08-06) have shown 30-day returns between 2.3% and 10.3%, with no measurable 90-day outcomes yet available. The current stock price of $48.95 is 8.6% below the 52-week high of $53.55, following a 3.6% 30-day gain and 19.6% 90-day gain. The filing presents a material position reduction by the CEO during a period of strong recent price appreciation, warranting monitoring of near-term price behavior and any forward guidance updates.

CEO Anish Bhatnagar sold 115,004 shares for $5.5M across 4 trades (Aug 28-29); stock near 52-week high at $48.95.

Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics, executed 4 separate sales totaling 115,004 shares for $5,454,707.26 at a blended average price of $47.43, reducing his holdings by 13.4% to 741,186 shares. The timing is noteworthy: the stock is currently trading at $48.95, only 6.5% below its 52-week high of $52.35, and the company is unprofitable with a net income of $-21,854,000 over its most recent full fiscal year. Across his open-market history at all tickers, Bhatnagar's prior sells have shown a 90-day well-timed rate of 20.00% (average 90-day return after selling was +50.0%, indicating poorly-timed sales overall). At this specific ticker, his 5 prior trades are all very recent (August 5–6) with outcomes not yet measurable. The scale and timing of this sale—moving a substantial block near the 52-week high in a therapeutics firm burning cash—deserves investor scrutiny of the underlying business drivers and any concurrent corporate developments.

CEO Bhatnagar sold 127.3K shares for $5.8M (blended avg $45.60) across 5 trades over Aug 5-6

Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics, executed 5 separate sales totaling 127,344 shares (127.3K shares) for $5,806,696.13 ($5.8M) at a blended average price of $45.60, reducing his holdings by 12.9% from 983.5K to 856.2K shares. The timing is notable against the backdrop of his prior trading record at this ticker: of 5 prior SLNO trades, 2 of 3 measurable 90-day outcomes showed negative returns (well-timed sells at -0.8% and -2.1%), while one showed a +24.7% gain (poorly timed); at the cross-ticker level, his track record shows 12 prior sells with a 90-day well-timed rate of 20.00%, indicating that only 1 in 5 of his sells historically preceded declines. The company's fundamentals present a cautionary context: it reported a $-21.9M net loss over its most recent full fiscal year, though it showed strong annual revenue growth of +138.8%, and currently trades at $43.96, which is 16.0% below its 52-week high of $52.35. This sale represents material liquidation by a top executive of a small unprofitable biotech firm, warranting examination of whether it signals internal concerns or reflects standard portfolio rebalancing consistent with the prior trading pattern.

CEO Anish Bhatnagar sold 19,256 shares for $799,843.97 across 2 transactions on 2024-07-01, reducing stake by 12.6%.

Anish Bhatnagar, CEO of Soleno Therapeutics, executed 2 separate sales totaling 19,256 shares for $799,843.97 on 2024-07-01 at an average price of $41.54, reducing his holdings from 152,790 to 133,534 shares. Against Soleno's fundamentals—a company reporting Revenue $1,000.00 in the latest quarter, Net income $-21,398,000.00, and unprofitability despite Annual revenue growth of +138.8%—the sale represents material position reduction. His prior 5 trades at this ticker show mixed timing outcomes: 2 of 5 were well-timed at the 90-day mark, suggesting inconsistent sell pattern recognition. At the transaction prices of $41.22 and $41.63, the CEO sold near the current price of $42.03 (within recent range), offering no signal of valuation timing or urgency.